Can I Take Magnesium with Rezdiffra (Resmetirom)?

What Is Resmetirom and Why Does Magnesium Come Up?

Resmetirom is a first-in-class, liver-targeted thyroid hormone receptor beta (THR-beta) selective agonist approved by the FDA on March 14, 2024, for adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-advanced liver fibrosis (F2-F3) [1]. It reduces hepatic fat by mimicking thyroid hormone action specifically in liver tissue while sparing the heart, bone, and muscle from systemic thyroid effects [2].

Magnesium enters the conversation for two reasons. First, MASH patients commonly use proton pump inhibitors (PPIs) for gastroesophageal reflux and thiazide or loop diuretics for hypertension or edema. Both drug classes are well-documented causes of hypomagnesemia [3]. Second, magnesium itself has direct relevance to insulin sensitivity and hepatic lipid metabolism, which are the same biological processes resmetirom is working to correct.

Resmetirom's Mechanism in Brief

Resmetirom binds selectively to THR-beta in hepatocytes, increasing fatty acid beta-oxidation, reducing de novo lipogenesis, and improving low-density lipoprotein receptor recycling [2]. In MAESTRO-NASH (N=966), resmetirom 100 mg produced MASH resolution in 25.9% of patients versus 14.2% placebo (P<0.001) and fibrosis improvement of at least one stage in 24.2% versus 14.2% placebo (P<0.001) [4].

Why Magnesium Status Matters in MASH

Magnesium acts as a cofactor for more than 300 enzymatic reactions, including those governing glucose transporter 4 (GLUT4) activity and insulin receptor tyrosine kinase signaling [5]. A 2018 meta-analysis of 18 prospective cohort studies (N=623,634) found that each 100 mg/day increase in dietary magnesium intake was associated with a 15% lower risk of type 2 diabetes (RR 0.85, 95% CI 0.80-0.91) [6]. Because insulin resistance is a defining feature of MASH, a patient whose magnesium is depleted may experience a pharmacodynamic offset of some of resmetirom's metabolic benefits.

Is There a Direct Drug Interaction Between Resmetirom and Magnesium?

No direct pharmacokinetic interaction between resmetirom and magnesium has been identified in the Rezdiffra prescribing information or in published pharmacokinetic studies [1]. The two substances do not compete for the same metabolic enzymes, transporters, or binding sites.

Pharmacokinetic Profile of Resmetirom

Resmetirom is absorbed in the small intestine, reaches peak plasma concentration in approximately 4 hours, and is metabolized primarily by CYP3A4 with minor contributions from CYP2C8 [1]. It is also a P-glycoprotein (P-gp) substrate. Magnesium ions do not inhibit or induce CYP3A4, CYP2C8, or P-gp at any physiologically relevant concentration [7]. A divalent cation chelation effect, the type seen with tetracycline antibiotics or fluoroquinolones, has not been described for resmetirom's chemical structure [1].

The Pharmacodynamic Concern

The real issue is indirect. If concurrent PPI or diuretic therapy depletes serum magnesium below approximately 0.75 mmol/L, insulin resistance worsens [8]. Resmetirom's benefits include improving hepatic insulin signaling downstream of THR-beta activation [2]. A patient who is magnesium-depleted may therefore experience a blunted metabolic response, not because resmetirom and magnesium interact chemically, but because two physiological processes are working against each other.

The FDA-approved prescribing information for Rezdiffra does not list magnesium among drug interactions. The relevant interaction category for magnesium is CYP3A4 inducers and inhibitors, and divalent cations simply do not fall into that class [1].

How Do PPIs and Diuretics Deplete Magnesium in MASH Patients?

MASH rarely arrives alone. Most patients carry a metabolic syndrome cluster: type 2 diabetes, hypertension, dyslipidemia, and obesity. Medications used to manage those comorbidities are a leading cause of acquired hypomagnesemia.

Proton Pump Inhibitors

Long-term PPI use (generally defined as more than one year) impairs active magnesium transport in the colon by downregulating the transient receptor potential melastatin 6 and 7 (TRPM6/7) channels [3]. The FDA issued a drug safety communication in 2011 requiring PPI labeling to include hypomagnesemia as a risk [9]. A 2020 population-based cohort study (N=59,572) found that PPI users had a 43% higher odds of hypomagnesemia compared with non-users (OR 1.43, 95% CI 1.28-1.60) [10]. Among patients on both a PPI and a diuretic, the odds were substantially higher.

Thiazide and Loop Diuretics

Thiazide diuretics increase urinary magnesium excretion by reducing passive reabsorption in the distal convoluted tubule [3]. Loop diuretics such as furosemide impair magnesium reabsorption in the thick ascending limb of the loop of Henle. Chronic use of either class can reduce serum magnesium by 0.1-0.3 mmol/L, enough to shift many patients from the normal range (0.75-1.1 mmol/L) into a clinically relevant deficit [11].

What This Means for the Resmetirom Patient

A MASH patient taking resmetirom who is also on a PPI and a thiazide diuretic carries compounding depletion risk. Checking a serum magnesium level at resmetirom initiation costs about $10 and provides actionable data. The Endocrine Society's 2023 clinical practice guideline on metabolic dysfunction-associated steatohepatitis recommends metabolic monitoring at baseline and at least every six months during pharmacotherapy [12].

What Does Magnesium Do for Liver Health Specifically?

Magnesium's role in hepatic metabolism extends well beyond glucose handling.

Hepatic Lipid Metabolism

Magnesium is a required cofactor for acetyl-CoA carboxylase, the rate-limiting enzyme in de novo lipogenesis, and for the magnesium-dependent ATPases that drive mitochondrial beta-oxidation [5]. Animal models of dietary magnesium deficiency show accelerated hepatic steatosis and elevated hepatic triglyceride content [13]. This mechanistically overlaps with resmetirom's target pathways: both aim to reduce hepatic fat accumulation through complementary routes.

Oxidative Stress and Inflammation

Magnesium deficiency promotes NF-kB activation and upregulates pro-inflammatory cytokines including TNF-alpha and IL-6, which are central to MASH pathogenesis [14]. A 2021 randomized controlled trial (N=64 adults with non-alcoholic fatty liver disease) found that 300 mg/day magnesium oxide supplementation for 24 weeks significantly reduced alanine aminotransferase (ALT, mean reduction 12.4 IU/L, P<0.05) and hepatic steatosis score on ultrasound compared with placebo [15].

Fibrosis Pathway Overlap

Magnesium also modulates TGF-beta1 signaling, one of the primary drivers of hepatic stellate cell activation and fibrosis [14]. Resmetirom demonstrated at least one-stage fibrosis improvement in 24.2% of patients in MAESTRO-NASH versus 14.2% placebo [4]. Whether adequate magnesium status potentiates that anti-fibrotic benefit has not been tested in a prospective RCT, but the mechanistic rationale is clear.

Practical Guidance: Taking Magnesium with Rezdiffra

The following decision framework reflects HealthRX clinical guidance for patients currently on or initiating resmetirom therapy who want to use magnesium supplementation.

Step 1: Check Serum Magnesium Before Starting

Request a serum magnesium level at resmetirom initiation or at your next scheduled visit. A result below 0.75 mmol/L warrants correction before attributing any suboptimal metabolic response to resmetirom. Normal range is 0.75-1.1 mmol/L in most U.S. Laboratory reference intervals [11].

Step 2: Choose the Right Form of Magnesium

Not all magnesium supplements are equivalent. Magnesium glycinate and magnesium citrate have higher bioavailability and lower rates of osmotic diarrhea compared with magnesium oxide [16]. For patients with MASH and concurrent gastrointestinal sensitivity, glycinate is often the preferred form. Magnesium oxide delivers more elemental magnesium per capsule but absorbs poorly (absorption approximately 4% vs. Approximately 67% for glycinate) [16].

| Form | Elemental Mg per 500 mg capsule | Estimated absorption | |---|---|---| | Magnesium oxide | ~300 mg | ~4% | | Magnesium citrate | ~80 mg | ~25-30% | | Magnesium glycinate | ~100 mg | ~60-70% |

Step 3: Timing and Dose

Take magnesium at least two hours before or after resmetirom. This is a conservative precaution based on the general principle that divalent cations can impair absorption of some orally administered drugs, even though no specific chelation data exist for resmetirom [1]. Resmetirom is taken once daily with or without food, typically in the morning. Magnesium glycinate 200-400 mg elemental magnesium daily (in divided doses if needed) falls within the NIH Office of Dietary Supplements' tolerable upper intake level of 350 mg/day from supplemental sources for adults [17].

Step 4: Monitor and Adjust

Recheck serum magnesium 6-8 weeks after starting supplementation. If levels normalize and gastrointestinal tolerance is good, continue at the established dose and recheck every three to six months. Patients on PPIs or diuretics may need ongoing supplementation rather than a time-limited course [3].

Drug Interactions That Actually Matter for Resmetirom

Since magnesium does not rank as a significant pharmacokinetic concern, patients and clinicians should reserve vigilance for the interactions the prescribing information does flag.

CYP3A4 Inhibitors and Inducers

Strong CYP3A4 inhibitors such as clarithromycin, itraconazole, and ritonavir may increase resmetirom plasma exposure by reducing hepatic clearance [1]. Strong inducers such as rifampin and carbamazepine may reduce resmetirom exposure substantially, potentially below therapeutic thresholds. The FDA label recommends avoiding co-administration with strong CYP3A4 inducers [1].

Statins

Resmetirom inhibits OATP1B1 and OATP1B3 hepatic uptake transporters, which are responsible for statin delivery to the liver. Co-administration with rosuvastatin, atorvastatin, or simvastatin may increase statin plasma concentrations and thereby raise the risk of myopathy [1]. The prescribing information recommends limiting rosuvastatin to 20 mg/day and simvastatin to 20 mg/day when co-administered with resmetirom [1].

Bile Acid Sequestrants

Cholestyramine and colesevelam can bind resmetirom in the gastrointestinal tract and reduce its absorption. A minimum four-hour separation window is recommended when co-administering these agents [1].

What the Evidence Says About Magnesium in MASH Populations

Published data specifically examining magnesium supplementation in MASH patients on resmetirom does not yet exist. Resmetirom received FDA approval in March 2024, and post-marketing observational data are still accumulating. The evidence base relies on adjacent data.

A 2020 cross-sectional analysis of NHANES data (N=3,869 adults) found that serum magnesium levels were inversely associated with hepatic steatosis on liver ultrasound, with the lowest magnesium quartile carrying a 62% higher prevalence of steatosis (OR 1.62, 95% CI 1.18-2.22) [18]. A separate 2022 meta-analysis of seven RCTs (N=374) examining magnesium supplementation in non-alcoholic fatty liver disease found significant reductions in fasting glucose, insulin, HOMA-IR, and ALT compared with placebo, though study quality varied and the longest trial was 24 weeks [19].

The Endocrine Society states: "Optimization of metabolic comorbidities, including micronutrient status, is recommended as part of comprehensive MASH management" [12]. While this is not a specific directive about magnesium, it supports the practice of correcting documented deficiencies during pharmacotherapy.

Monitoring Checklist for Patients on Resmetirom

Resmetirom carries its own monitoring requirements independent of magnesium. Understanding the full picture helps patients and clinicians integrate magnesium assessment without additional confusion.

Liver Function Tests

ALT and AST should be checked at baseline, at 3 months, and every 6 months thereafter. In MAESTRO-NASH, ALT elevations greater than three times the upper limit of normal occurred in approximately 4% of resmetirom-treated patients versus 1.8% placebo [4]. Drug-induced liver injury with resmetirom is uncommon but warrants monitoring.

Lipid Panel

Resmetirom significantly reduces LDL cholesterol (median reduction approximately 16% at 100 mg in MAESTRO-NASH) [4] and triglycerides. The same lipid panel that monitors resmetirom response can also prompt a conversation about statin dose adjustment and the OATP1B1/1B3 interaction discussed above.

Thyroid Function

Despite THR-beta selectivity, TSH should be monitored at baseline and annually. No clinically significant suppression of TSH was observed in MAESTRO-NASH, but individual variation exists [4].

Serum Magnesium Integration

Adding serum magnesium to the baseline draw and every-6-month panel requires no additional patient visit. For patients on PPIs or diuretics, a 3-month check after the baseline may be warranted.

When to Talk to Your Prescribing Clinician

Patients should contact their prescribing clinician before starting any magnesium supplement if any of the following apply: chronic kidney disease stage 3b or higher (eGFR <45 mL/min/1.73m²), because impaired renal clearance raises the risk of hypermagnesemia [17]; concurrent use of magnesium-containing antacids that could push total intake above the upper tolerable limit; or unexplained muscle weakness or cardiac symptoms, which in the context of magnesium supplementation could indicate over-supplementation or a separate electrolyte disturbance.

The NIH Office of Dietary Supplements notes: "People with impaired kidney function are at higher risk of adverse effects from excess magnesium" [17]. This is the population where supplementation needs explicit clinical oversight rather than self-directed use.